AdvaMed response letter to OMB’s RFI on deregulation, highlighting support for regulatory reform that fosters medical innovation and improved patient care, dated May 12, 2025.
Emerging Policy Response Resources / Government & Legislative Affairs / Legal

AdvaMed Comments to OMB Deregulation RFI

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.

A group of people sitting at an event and listening to a speaker
In Person

MedTech Compliance Bootcamp

Join AdvaMed & Porzio for this comprehensive compliance bootcamp to better understand the current medtech compliance framework.

Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Health Equity / Legal / Regulatory Affairs / Small Business

The Medical Innovation Agenda for the 119th Congress

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.